Stryker Corporation (SYK)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$326.91-0.86%
Close 2026-07-08 · 1-day change
Reading SYK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SYK free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading SYK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SYK free→Warn: Management is running behind on a stated commitment.
Stryker grows sales about 8.75% a year as it expands its trauma and orthopedic products. Profit per share stays near $15 in 2026. New products and acquisitions support steady growth. The company manages cybersecurity risks and keeps costs controlled.
Sales growth slows below 8%. Profit per share falls below $14.90. Cybersecurity issues or litigation disrupt operations. New product launches fail to gain traction.
The current price reflects about 11% revenue growth and EPS near $15 for 2026. Our view aligns with these expectations but sees risk if growth or profit weakens.
Breaks if: Adjusted EPS falls below $14.90 in FY26
Stryker aims to maintain adjusted EPS guidance in the range of $14.90 to $15.10 for 2026.
Stated in 6 of last 6 quarters. Adjusted EPS decreased 8.5% in 2026-Q1, from $2.84 in 2025-Q1 to $2.60 in 2026-Q1. Despite maintaining guidance, the trajectory shows limited progress towards the target range.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We remain committed to meeting our full year guidance for adjusted earnings per share.”
“We expect adjusted net earnings per diluted share to be in the range of $14.90 to $15.10.”
“We are raising our full year 2025 guidance and now expect adjusted net earnings per diluted share to be in the range of $13.50 to $13.60.”
“We are raising our full year 2025 guidance and now expect adjusted net earnings per diluted share to be in the range of $13.40 to $13.60.”
“We expect our adjusted net earnings per diluted share to be the range of $13.20 to $13.45.”
“We expect adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.”
Breaks if: Material operational disruption or new cybersecurity incidents occur
Stryker is focused on addressing the cybersecurity incident that affected its IT systems.
Breaks if: YoY revenue growth falls below 8.0% in FY26
Stryker aims to maintain organic net sales growth in the range of 8.0% to 9.5% for 2026.
Stated in 6 of last 6 quarters. Revenue grew from $5.9B in 2025-Q1 to $6.0B in 2026-Q1. Despite maintaining guidance, the growth trajectory shows limited progress towards the upper end of the target range.
“We remain committed to meeting our full year guidance for organic sales growth.”
“We expect 2026 organic net sales growth to be in the range of 8.0% to 9.5%.”
“We are raising our full year 2025 guidance and now expect organic net sales growth of 9.8% to 10.2%.”
“We are raising our full year 2025 guidance and now expect organic net sales growth of 9.5% to 10.0%.”
“We are raising our full year 2025 organic net sales growth guidance range to 8.5% to 9.5%.”
“We expect organic net sales growth to be in the range of 8.0% to 9.0% for 2025.”